Article
Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis.
BMC cancer - 7 May 2022
Xu Ziyi, Liu Chengcheng, Zhu Yixiang, Zou Zihua, Xie Tongji, Xing Puyuan, Wang Le, Li Junling
Abstract excerpt
OBJECTIVE: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the current standard of care for advanced or metastatic non-small cell lung cancer (NSCLC) patients harboring EGFR activating mutations. However, the optimal strategy for elderly NSCLC patients is still under debate. This study was designed to explore the optimal first-line regimens by comparing diverse strategies for elderly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.